Leadership Team




Bob Oliver

Bob Oliver

CEO

Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. As Vice President and Global Business Manager for Oncology at Wyeth, he led the global launch of Torisel for RCC and later assumed responsibility for U.S. Commercial Operations. Bob began his career in pharmaceuticals with Johnson & Johnson where he held positions of increasing responsibility. During his tenure at Otsuka, Bob held senior level executive roles including President & COO for North America and most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc. He currently maintains the position of Board Chairman for Otsuka Canada. Bob is also Executive Advisor and a member of the Board of Directors for Hyalo Technologies; as well as Board Member of Neurotez both Biotech start-ups. Previously Bob served on the board of Immunomedics a publicly traded company focused on Oncology. Bob holds a BA from Rutgers University and an MBA from Saint Joseph’s University.

Raghu Rao

John Soenksen

Interim CFO

John is an experienced bilingual global financial executive with a strong background working in both large and middle market companies. Most recently John served as CFO for a Flow Cytometry based CRO and Diagnostics development company. Just prior to this John was based in Singapore for 3.5 years as CFO for Tyco’s Asia-Pacific Installation and Services business with a revenue base of $1.9B. Prior to this John held the role of Tyco’s Vice President of Internal Audit. Additionally, he served in various other roles including as CFO of 2 public companies. John has experience with IPO’s, Mergers and Acquisitions as well as planning and directing complex global initiatives and is experienced in building strong teams to drive sustained performance. John began his career with PriceWaterhouseCoopers (PWC) in Philadelphia. He is a CPA (inactive) and holds a BA in Accounting from Muskingum University.

Subbu Apparsundaram

Subbu Apparsundaram

Chief Development Officer

Dr. Subbu Apparsundaram, Chief Development Officer, is an established scientist with extensive experience in drug discovery pharmacology, neuroscience, and immunology. He has solid experience in conceptualizing, formulating and implementing basic science to drug discovery strategies. He is highly skilled in target validation, lead identification and clinical candidate selection. Prior to founding V ClinBio, he was a Drug Discovery Scientist at Hoffmann-La Roche Pharmaceuticals, where he provided team leadership for neuroscience and inflammation projects and enabled research teams to achieve lead selection, lead optimization and clinical candidate selection milestones. He was also a faculty at the University of Kentucky Medical Center. He has published several peer reviewed research papers.

Subbu Apparsundaram

Klaus R. Krauser, DVM, PhD

Head of Pre-clinical Operations

Klaus has more than 30 years of experience in nonclinical drug development, preclinical safety testing and assessment of both small molecule and large molecule drugs of different formats, as well as of industrial chemicals and medical devices. Most recently he served as Senior Director Non-Clinical Innovation and R&D Strategy at Shire, previously Baxalta. Before he was Vice President Drug Safety at Thesan Pharmaceuticals in Carlsbad, CA, a dermatology development company, and Vice President Preclinical Development at Berg Health, Framingham, MA; he represented Nonclinical Safety at the Novartis Biotherapeutics Development Unit in San Diego, CA. Dr. Krauser is experienced in leading large teams, i.e. Global Preclinical Safety at Abbott, Global Toxicology at Merck/EMD Serono, Geneva, Switzerland, and Short- and Long-Term Toxicology at Schering AG (now Bayer) in Berlin, Germany. He also directly supported study and project activities in small to medium sized companies, i.e. Arena Pharmaceuticals, the developer of the obesity drug Lorcaserin (Belviq®), and ASTA Medica AG in Frankfurt, Germany, the inventor of Cyclophosphamide (Endoxan®). Dr. Krauser contributed to numerous INDs and CTAs as well as global marketing authorization filings (NDAs, BLAs), e.g. Humira®, TriCor®, Xience® coronary stents, Betaseron®, Yasmin®, Magnevist®, Belviq®, Erbitux®, new Rebif® formats, Astelin®, Optivar®, Ifex®, Impavido®, Cetrotide®. Klaus studied Veterinary Medicine at the Freie Universitaet in Berlin, Germany, from where he also received his PhD in Veterinary Pathology. He is a Diplomate of the European College of Veterinary Pathologists and German Board Certified in Veterinary Pathology and Toxicopathology as well as in Pharmacology and Toxicology.

Jaideep Khanna

Jaideep Khanna

Director

Jaideep Khanna is managing partner and co-founder of Artha Capital Management, an emerging market fund based in Stamford, CT. He co-founded the firm in April 2002 and served as president, portfolio manager and director. Prior to starting Artha, Jaideep was an executive director and managed pools of funds at Morgan Stanley Asset Management in New York and London. He serves on the New York Regional Board of Room to Read and on the National Board of Directors for Pratham USA. He was the founder and remains a trustee of Ashoka University, New Delhi, and serves on the International Advisory Board, Center for Advanced Study of India at the University of Pennsylvania. He received a degree in accounting and economics from Muskingum University and holds an MBA from Duke.

Advisory Board




Sheila Gujrathi

Sheila Gujrathi

Strategic Advisor

Dr. Gujrathi is an accomplished Physician Scientist with expertise in Clinical Development and Immunology disease area. Dr. Gujrathi served as the Chief Medical Officer of Receptos, Inc which was acquired by Celgene Corporation. Dr. Gujrathi also served as Vice President of the Global Clinical Research Group in Immunology at Bristol-Myers Squibb Company. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group. Dr. Gujrathi also served as a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in Biomedical Engineering and M.D. from Northwestern University in their accelerated honors program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.

Ashok Nigalaye

Ashok Nigalaye

Product Consultant

Dr. Ashok Nigalaye is a successful biotech entrepreneur with product formulation expertise in tablets and capsule dosage forms. He has successful exits as CEO of Epic Pharma and CSO of Elite Pharmaceuticals. He has a PhD in Industrial Pharmacy.

Paul Jeffery

Paul Jeffrey

Business Consultant

Paul Jeffrey is an accomplished Pharmaceutical business consultant and leader with demonstrated new product development and business development capabilities. He has over 30 years of industry experience building product value by leading global teams and creating and implementing clinical and marketing programs to maximize commercial positioning and launch success. He has led commercial development teams for multiple products that achieved over $1 billion in sales. He also held key roles in designing multiple alliance partnerships and in closing high value business development deals while at Pfizer as VP of Global Commercial Development group.